Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


STOCKWATCH: Cycles and irrational valuations

This article was originally published in Scrip

Executive Summary

US publicly-quoted biotechnology appears as wildly expensive as it was in the bubble period of 2000. At that time, $2.5 billion was raised by biotech companies between July and August and the share prices of biotechs without any earnings were justified by optimistic earnings per share (EPS) multiples of 100 or more in the hope that these earnings would eventually appear. For reference, the valuation of revenue-generating established pharma companies at that time was based on EPS multiples around 15 (in 2012, 10 is more typical)



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts